

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 July 2022 (21.07.2022)



(10) International Publication Number
WO 2022/153166 A1

(51) **International Patent Classification:**
C07K 14/245 (2006.01) A61P 13/00 (2006.01)

(21) **International Application Number:**
PCT/IB2022/050166

(22) **International Filing Date:**
11 January 2022 (11.01.2022)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
21151126.6 12 January 2021 (12.01.2021) EP

(71) **Applicant: JANSSEN PHARMACEUTICALS, INC.**
[US/US]; 1125 Trenton-Harbourton Road, Titusville, New
Jersey 08560 (US).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(72) **Inventors: GRIJPSTRA, Jan;** Archimedesweg 4-6, 2333 CN Leiden (NL). **WEERDENBURG, Eveline, Marleen;** Archimedesweg 4-6, 2333 CN Leiden (NL). **GEURTSSEN, Jeroen;** Archimedesweg 4-6, 2333 CN Leiden (NL). **FAE, Kellen, Cristhina;** Archimedesweg 4-6, 2333 CN Leiden (NL). **FEITSMA, Louris, Jakob;** c/o Janssen Vaccines & Prevention B.V., IP Department, Archimedesweg 4-6, 2333 CN Leiden (NL).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** FIMH MUTANTS, COMPOSITIONS THEREWITH AND USE THEREOF

(57) **Abstract:** Polypeptides comprising a FimH lectin domain comprising at least one amino acid mutation that causes the FimH lectin domain to be in the low affinity conformation for mannose are described. Pharmaceutical compositions which comprise such polypeptides and methods of stimulating an immune response in a subject in need thereof by administration of the polypeptide are further described.



WO 2022/153166 A1